BiotechTube
All Reports
⚡

Metabolic & Endocrine

Competitive landscape report · 114 products · 20 companies

Executive Summary

The metabolic & endocrine landscape features 114 products in active development across 20 companies. The space remains highly competitive with significant activity across all clinical stages.

31 products are currently in Phase 3 trials, 19 in Phase 2, and 29 in Phase 1. Leading companies by pipeline count include Eli Lilly, GEROPHARM, Celltrion.

16 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.

Top Products by Hype Score

1
exenatide + PlaceboObesity
Eli Lilly
Approved
85
2
Insulin Lispro Mix25 + Insulin Lispro Mix50Type 2 Diabetes Mellitus
Eli Lilly
Approved
85
3
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Diabetes Mellitus, Type 2
Eli Lilly
Approved
85
4
exenatide and sitagliptin + exenatide and placeboType 2 Diabetes Mellitus
Eli Lilly
Approved
85
5
Tirzepatide + PlaceboType II Diabetes
Eli Lilly
Approved
85
6
LisproDiabetes Mellitus, Type 2
Eli Lilly
Approved
85
7
insulin lispro protamine suspension:insulin lispro rDNA origin low mix + insulin glargineType 2 Diabetes
Eli Lilly
Approved
85
8
Insulin Analog Mid Mixture + Basal Insulin AnalogType 2 Diabetes Mellitus
Eli Lilly
Approved
85
9
Insulin GlargineType 2 Diabetes Mellitus
Eli Lilly
Approved
85
10
TirzepatideObesity
Eli Lilly
Approved
85

Top Companies by Pipeline Count

1Eli Lilly73 products2GEROPHARM12 products3Celltrion4 products4MBX Biosciences3 products5Perspective Therapeutics3 products6Unity Biotechnology3 products7Merck2 products8KalVista Pharmaceuticals2 products9Amgen1 products10Clearside Biomedical1 products

Phase Distribution

Pre-clinical
12
Phase 1
29
Phase 1/2
5
Phase 2
19
Phase 2/3
2
Phase 3
31
Approved
16

Key Trends & Analysis

Pro

Market consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.

Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.

Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.

Upgrade to Pro for full analysis

View plans
Back to all reports